Empagliflozin
Empagliflozin is an SGLT2 inhibitor taken by mouth to lower the risk of cardiovascular death and hospital stays in heart failure, to protect the kidneys in chronic kidney disease, to lower cardiovascular death risk in type 2 diabetes with cardiovascular disease, and to improve blood sugar control in type 2 diabetes.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 9 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Empagliflozin (Jardiance) is a once-daily tablet that makes the kidneys flush extra sugar and salt into the urine, which lowers blood sugar and eases strain on the heart and kidneys; on the market since about 2014, it is now a mainstay for heart failure and chronic kidney disease and a common add-on in type 2 diabetes. Most people tolerate it well, noticing mainly more urination and thirst, plus genital yeast or urinary infections for some. Watch for ketoacidosis (a dangerous acid buildup in the blood), which can strike even with normal blood sugar; get help right away for nausea, vomiting, stomach pain, unusual tiredness or trouble breathing.
Clinical pearls
- Tell your care team about sick days or surgery needing prolonged fasting; it may need pausing, sometimes at least 3 days ahead.
- Taken with insulin or a sulfonylurea, it can cause low blood sugar, so those doses may be lowered when you start.
- Urine sugar tests will read positive and 1,5-AG blood tests become unreliable, so track sugar with fingersticks or an A1C.
- Drink fluids steadily, especially with a water pill, which adds to dehydration risk; with lithium, levels can drop and need closer checks.
Patient information guide A plain-language walkthrough of Empagliflozin, written from its FDA label.
What Empagliflozin is used for
▾
Empagliflozin is used for heart, kidney, and blood sugar conditions. These uses come from Jardiance tablets.
- Jardiance reduces the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
- Jardiance reduces the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
- Jardiance reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
- Jardiance is used with diet and exercise to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes.
It is not recommended for blood sugar control in type 1 diabetes, or in type 2 diabetes with an eGFR below 30.
How Empagliflozin works
▾
Empagliflozin blocks SGLT2, a kidney protein that returns sugar from the filtered fluid back into the blood. Blocking it makes your body pass more sugar in the urine, which lowers blood sugar.
It also reduces sodium reabsorption in the kidneys. This may lower pressure inside the kidney's filters and ease the load on the heart.
Empagliflozin dosage
▾
Jardiance is a tablet taken by mouth once daily in the morning, with or without food. Your prescriber chooses the dose, and for blood sugar control it may be raised if you tolerate it.
- If you miss a dose, take it as soon as you can.
- Do not double up the next dose.
- Kidney function and hydration should be checked before starting.
- You may need to pause it for at least 3 days before surgery or procedures with prolonged fasting, if possible.
Dosing details from the FDA-approved label
From the Empagliflozin prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults: Reduce the risk of cardiovascular death and hospitalization in patients with heart failure
- 10 mg orally once daily in the morning, taken with or without food
- Assess renal function and volume status before initiating; correct volume depletion first.
- Adults: Reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression
- 10 mg orally once daily in the morning, taken with or without food
- Assess renal function and volume status before initiating; correct volume depletion first.
- Adults: Reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus with established cardiovascular disease
- 10 mg orally once daily in the morning, taken with or without food
- Assess renal function and volume status before initiating; correct volume depletion first.
- Adults: Glycemic control in type 2 diabetes mellitus
- 10 mg orally once daily in the morning, taken with or without food
- For additional glycemic control, may increase to 25 mg orally once daily in patients tolerating 10 mg once daily
- Maximum: 25 mg orally once daily
- Use for glycemic control is not recommended in patients with an eGFR less than 30 mL/min/1.73 m2.
- Pediatric patients aged 10 years and older: Glycemic control in type 2 diabetes mellitus
- 10 mg orally once daily in the morning, taken with or without food
- For additional glycemic control, may increase to 25 mg orally once daily in patients tolerating 10 mg once daily
- Maximum: 25 mg orally once daily
- Use for glycemic control is not recommended in patients with an eGFR less than 30 mL/min/1.73 m2.
- Temporary interruption for surgery or procedures associated with prolonged fasting
- Withhold JARDIANCE for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting
- Resume when the patient is clinically stable and has resumed oral intake
- Missed dose
- Take the dose as soon as possible
- Do not double up the next dose
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating. ( 2.1 ) • Recommended dosage is 10 mg orally once daily in the morning, taken with or without food. ( 2.2 ) • For additional glycemic control, dosage may be increased to 25 mg orally once daily in patients tolerating JARDIANCE. ( 2.2 ) • Withhold JARDIANCE for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting. ( 2.3 ) 2.1 Testing Prior to Initiation of JARDIANCE • Assess renal function before initiating JARDIANCE and as clinically indicated [see Warnings and Precautions (5.2) ] . o Use for glycemic control is not recommended in patients with an eGFR less than 30 mL/min/1.73 m 2 [see Use in Specific Populations (8.6) ]. • Assess volume status. In patients with volume depletion, correct this condition before initiating JARDIANCE [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5 , 8.6) ]. 2.2 Recommended Dosage Table 1 presents the recommended dosage of JARDIANCE in adult and pediatric patients aged 10 years and older. Table 1 Recommended Dosage of JARDIANCE Population Indication Recommended Dosage Adults Reduce the risk of cardiovascular death and hospitalization in patients with heart failure • 10 mg orally once daily in the morning, taken with or without food. Reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. Reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus with established cardiovascular disease Glycemic control in type 2 diabetes mellitus • 10 mg orally once daily in the morning, taken with or without food. • For additional glycemic control, may increase to 25 mg orally once daily in patients tolerating 10 mg once daily. Pediatric patients aged 10 years and older Glycemic control in type 2 diabetes mellitus • 10 mg orally once daily in the morning, taken with or without food. • For additional glycemic control, may increase to 25 mg orally once daily in patients tolerating 10 mg once daily. 2.3 Temporary Interruption for Surgery Withhold JARDIANCE for at least 3 days, if possible, prior to surgery or procedures associated with prolonged fasting.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Empagliflozin side effects
▾
Most side effects relate to extra sugar and fluid passing through the urinary tract.
Common side effects
- Urinary tract infections
- Genital yeast infections (more common in women)
- Increased urination
- Thirst
- Upper respiratory tract infection
- Joint pain
- Nausea
- Low blood sugar when used with insulin or sulfonylureas
When to get medical help
- Get medical help right away for nausea, vomiting, stomach pain, unusual tiredness, or trouble breathing. These can be signs of ketoacidosis (a buildup of acids in the blood), which can happen even when blood sugar is not very high.
- Call your doctor about signs of dehydration or low blood pressure, such as dizziness, fainting, or feeling lightheaded.
- Seek care promptly for pain, tenderness, redness, or swelling in the genital or groin area with fever or feeling unwell. This can signal a rare, serious infection called Fournier's gangrene.
- Call your doctor for signs of a urinary tract infection or kidney infection. Serious cases have required hospitalization.
- Report new pain, sores, ulcers, or infection in your legs or feet right away.
- Stop the medicine and get urgent help for signs of a serious allergic reaction, such as swelling of the face, lips, or throat.
- Watch for symptoms of low blood sugar, especially if you take insulin or a sulfonylurea.
Get help quickly for signs of ketoacidosis, dehydration, a severe genital-area infection, a kidney or serious urinary infection, foot or leg sores, or an allergic reaction.
Empagliflozin warnings and precautions
▾
Ketoacidosis is the most serious risk. It can happen even when blood sugar is not very high. Warning signs include nausea, vomiting, stomach pain, unusual tiredness, and trouble breathing. Stop the medicine and get help right away if they occur.
- Dehydration and low blood pressure: higher risk with kidney problems, older age, or loop diuretics.
- Urinary infections: serious cases, including kidney infections, have needed hospital care.
- Fournier's gangrene: rare, serious genital-area infection. Watch for pain, redness, or swelling with fever.
- Genital yeast infections: more likely if you have had them before.
- Leg and foot amputations: risk is highest with diabetic foot problems or poor circulation. Practice routine foot care.
- Low blood sugar: higher with insulin or sulfonylureas. In children 10 and older, the risk was higher regardless of insulin.
- Allergic reactions: including swelling of the face or throat.
Empagliflozin interactions
▾
Some medicines and tests change how empagliflozin works or how it is monitored.
- Diuretics: more urine output can lead to dehydration.
- Insulin or sulfonylureas: higher chance of low blood sugar, so doses may need lowering.
- Lithium: levels may drop, so they should be checked more often.
- Urine glucose tests: will read positive, so use other ways to track blood sugar.
- 1,5-AG tests: unreliable while taking this medicine.
Interactions listed in the FDA-approved label
From the Empagliflozin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Diuretics: Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion. Before initiating JARDIANCE, assess volume status and renal function. In patients with volume depletion, correct this condition before initiating. Monitor for signs and symptoms of volume depletion, and renal function after initiating therapy.
- Insulin or insulin secretagogues (e.g., sulfonylurea): The risk of hypoglycemia is increased when JARDIANCE is used in combination with insulin secretagogues or insulin. May require lower dosages of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.
- Lithium: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently during JARDIANCE initiation and dosage changes.
- Positive urine glucose test: SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Monitoring glycemic control with urine glucose tests is not recommended. Use alternative methods to monitor glycemic control.
- 1,5-anhydroglucitol (1,5-AG) assay: Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Monitoring glycemic control with 1,5-AG assay is not recommended. Use alternative methods to monitor glycemic control.
Read the label’s full interactions text
7 DRUG INTERACTIONS See Table 4 for clinically relevant interactions with JARDIANCE. Table 4 Clinically Relevant Interactions with JARDIANCE Diuretics Clinical Impact Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion. Intervention Before initiating JARDIANCE, assess volume status and renal function. In patients with volume depletion, correct this condition before initiating JARDIANCE. Monitor for signs and symptoms of volume depletion, and renal function after initiating therapy. Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia is increased when JARDIANCE is used in combination with insulin secretagogues (e.g., sulfonylurea) or insulin. Intervention Coadministration of JARDIANCE with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower dosages of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. Lithium Clinical Impact Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. Intervention Monitor serum lithium concentration more frequently during JARDIANCE initiation and dosage changes. Positive Urine Glucose Test Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Intervention Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control. Interference with 1,5-anhydroglucitol (1,5-AG) Assay Clinical Impact Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Intervention Monitoring glycemic control with 1,5-AG assay is not recommended. Use alternative methods to monitor glycemic control. See full prescribing information for information on drug interactions and interference of JARDIANCE with laboratory tests. ( 7 )
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Empagliflozin
▾
- Do not use if you have had a serious allergic reaction to empagliflozin or any ingredient in Jardiance.
- Do not use if you have severe kidney impairment, end-stage kidney disease, or are on dialysis.
- Not recommended for blood sugar control in type 1 diabetes.
- Not recommended during the second and third trimesters of pregnancy, based on animal kidney findings.
- Not recommended while breastfeeding.
- Children: approved for blood sugar control in type 2 diabetes from age 10. Safety and effectiveness for heart and kidney uses have not been established in children.
- Older adults: higher chance of dehydration-related side effects and urinary infections, especially age 75 and older.
- Kidney problems: blood sugar lowering weakens and side effects rise as kidney function declines.
- Tell your doctor about pancreas problems, frequent genital or urinary infections, or foot ulcers and poor circulation.
Empagliflozin overdose
▾
If you take too much Jardiance, contact Poison Control. Care focuses on supportive measures and monitoring based on how you are doing. Whether dialysis can remove empagliflozin has not been studied.
What Empagliflozin does in the body
▾
Empagliflozin makes the body pass more sugar in the urine, starting right after a dose. In people with type 2 diabetes, this was about 64 to 78 grams per day after 4 weeks. It also increases urine volume, most noticeably in the first days. Sugar loss returns toward baseline about 3 days after a single dose. In a study of healthy people, it did not lengthen the QTc interval (a heart rhythm measure).
How your body processes Empagliflozin
▾
After you swallow it, empagliflozin peaks in the blood at about 1.5 hours. Food slightly lowers absorption, but not in a way that matters, so you can take it with or without food. The half-life is about 12.4 hours. It is mainly broken down by glucuronidation, a process that makes drugs easier to remove, and cleared through urine and stool. Levels rise with kidney or liver impairment.
How to store Empagliflozin
▾
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Empagliflozin
257 supplements and herbal products have documented interactions with Empagliflozin in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 2
- Moderate · 216
- Minor · 39
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Empagliflozin has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Empagliflozin: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Empagliflozin — the kind of thing our pharmacy team would talk through with you at the counter.
What is Jardiance (empagliflozin) used for?
▾
How and when should I take it?
▾
What side effects should I expect?
▾
When should I get help right away?
▾
Do I need to adjust my other medicines?
▾
Is it safe during pregnancy or breastfeeding?
▾
Is Empagliflozin available over the counter?
▾
When was Empagliflozin first available?
▾
Who makes Empagliflozin?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Empagliflozin on HelloPharmacist
Empagliflozin forms and strengths (how it comes)
Empagliflozin is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Jardiance is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
- Jardiance is used in adults with chronic kidney disease at risk of progression.
- Jardiance is used to lower cardiovascular death risk in adults with type 2 diabetes and established cardiovascular disease.
- Jardiance is used with diet and exercise to improve blood sugar control in type 2 diabetes in adults and children aged 10 and older.
- Jardiance is taken by mouth once daily in the morning, with or without food.
- Jardiance may be paused for at least 3 days before surgery or procedures with prolonged fasting, if possible.
- If a Jardiance dose is missed, take it as soon as possible and do not double the next dose.
- Jardiance users should have kidney function and hydration status assessed before starting.
Empagliflozin on the U.S. market: products, makers and brands
How Empagliflozin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
5 companies list 11 Empagliflozin product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2014. Brand names on the directory include Jardiance; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (28) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Empagliflozin is used (Medicaid data)
A general measure of how commonly Empagliflozin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Empagliflozin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Empagliflozin prescribed? Of the 1,601 medications we measure, Empagliflozin ranks #77 by Medicaid prescriptions — more than 95% of them.
Utilization by Empagliflozin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
empagliflozin 25 MG Oral Tablet Most dispensed
Summed across the 3 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1545666
empagliflozin 10 MG Oral Tablet
Summed across the 3 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1545658
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Empagliflozin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 6 of 33 listed Empagliflozin NDCs with Medicaid activity.
Compare Empagliflozin products
A representative set of FDA-listed product records for Empagliflozin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 10 mg | Oral | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 25 mg | Oral | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 10 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC | NDA | View NDC → |
| 25 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC | NDA | View NDC → |
| 10 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 25 mg | Oral | Boehringer Ingelheim Pharmaceuticals, Inc. | NDA | View NDC → |
| 10 mg | Oral | Cardinal Health 107, LLC | NDA | View NDC → |
| 25 mg | Oral | Cardinal Health 107, LLC | NDA | View NDC → |
| 25 mg | Oral | Redpharm Drug | NDA | View NDC → |
Showing 11 of 11 products — FDA National Drug Code Directory. See every product, package size and price: browse all 11 Empagliflozin NDCs →
Empagliflozin side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Empagliflozin — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Empagliflozin are diabetic ketoacidosis, nausea, blood glucose increased; about 0% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Empagliflozin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Empagliflozin FDA approval history
How Empagliflozin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Empagliflozin recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 2 Empagliflozin recalls since July 2021. None of them is still listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgef… Lots: Lot #: a) and b) E61835, exp. date JUN 2025 FDA record D-0468-2023 →
- Jardiance (empagliflozin tablets), 25 mg, 30 tablets (3 blister cards with 10 tablets each), Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877. NDC: 0597-0153-… Lots: Batch D41919 FDA record D-0185-2024 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1545653 1 dose form · 2 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 1545657In current FDA listings
Look up RxCUI 1545653 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Empagliflozin supply and shortage status
Whether Empagliflozin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Empagliflozin brand names
Empagliflozin is sold under one brand name in the FDA directory — Jardiance. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Empagliflozin: manufacturers and labelers
5 companies list Empagliflozin products with the FDA. By number of product records, the largest are A-S Medication Solutions, Aphena Pharma Solutions - Tennessee, LLC, Boehringer Ingelheim Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Empagliflozin drug class (RxNorm)
Empagliflozin belongs to the Sodium-Glucose Cotransporter 2 Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Empagliflozin page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Cardinal Health 107, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →